Literature DB >> 18512240

The role of PGP9.5 as a tumor suppressor gene in human cancer.

Yutaka Tokumaru1, Keishi Yamashita, Myoung Sook Kim, Hannah L Park, Motonobu Osada, Masaki Mori, David Sidransky.   

Abstract

PGP9.5 is a controversial molecule from an oncologic point of view. We recently identified frequent methylation of PGP9.5 gene exclusively in primary head and neck squamous cell carcinoma (HNSCC), suggesting that it could be a tumor suppressor gene. On the other hand, PGP9.5 was reported to be overexpressed in a subset of human cancers presumably due to intrinsic oncogenic properties or as a result of transformation. To demonstrate that PGP9.5 possesses tumor suppressive activity, we examined forced expression by stable transfection of PGP9.5 in 4 HNSCC cell lines. Although all 4 cell lines demonstrated reduced log growth rates in culture after transfection, only 2 cell lines with wild type p53 (011, 022) demonstrated decreased growth in soft agar. In 2 cell lines with mutant p53 (013, 019), we observed no altered growth in soft agar and increased sensitivity to UV irradiation. We then tested for and found a high frequency of promoter methylation in a larger panel of primary tumors including HNSCC, esophageal SCC, gastric, lung, prostate and hepatocellular carcinoma. Our data support the notion that PGP9.5 is a tumor suppressor gene that is inactivated by promoter methylation or gene deletion in several types of human cancers. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18512240      PMCID: PMC3069849          DOI: 10.1002/ijc.23354

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  Anti-angiogenic activity of torilin, a sesquiterpene compound isolated from Torilis japonica.

Authors:  M S Kim; Y M Lee; E J Moon; S E Kim; J J Lee; K W Kim
Journal:  Int J Cancer       Date:  2000-07-15       Impact factor: 7.396

2.  Methylation status in the promoter region of the human PGP9.5 gene in cancer and normal tissues.

Authors:  S L Bittencourt Rosas; O L Caballero; S M Dong; M da G da Costa Carvalho; D Sidransky; J Jen
Journal:  Cancer Lett       Date:  2001-09-10       Impact factor: 8.679

3.  PGP9.5 as a marker for invasive colorectal cancer.

Authors:  Taiji Yamazaki; Kenji Hibi; Tsunenobu Takase; Ekmel Tezel; Hiroshi Nakayama; Yasushi Kasai; Katsuki Ito; Seiji Akiyama; Tetsuro Nagasaka; Akimasa Nakao
Journal:  Clin Cancer Res       Date:  2002-01       Impact factor: 12.531

4.  PGP9.5 as a prognostic factor in pancreatic cancer.

Authors:  E Tezel; K Hibi; T Nagasaka; A Nakao
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

5.  The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility.

Authors:  Yichin Liu; Lara Fallon; Hilal A Lashuel; Zhihua Liu; Peter T Lansbury
Journal:  Cell       Date:  2002-10-18       Impact factor: 41.582

6.  AIS is an oncogene amplified in squamous cell carcinoma.

Authors:  K Hibi; B Trink; M Patturajan; W H Westra; O L Caballero; D E Hill; E A Ratovitski; J Jen; D Sidransky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

7.  PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma.

Authors:  Diana L Mandelker; Keishi Yamashita; Yutaka Tokumaru; Koshi Mimori; David L Howard; Yoichi Tanaka; Andre Lopes Carvalho; Wei-Wen Jiang; Hannah Lui Park; Myoung Sook Kim; Motonobu Osada; Masaki Mori; David Sidransky
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

8.  p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas.

Authors:  Bhuvanesh Singh; Pabbathi G Reddy; Andy Goberdhan; Christine Walsh; Su Dao; Ivan Ngai; Ting Chao Chou; Pornchai O-Charoenrat; Arnold J Levine; Pulivarthi H Rao; Archontoula Stoffel
Journal:  Genes Dev       Date:  2002-04-15       Impact factor: 11.361

9.  Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer.

Authors:  Kazuaki Nakanishi; Michiie Sakamoto; Jun Yasuda; Masaaki Takamura; Naoya Fujita; Takashi Tsuruo; Satoru Todo; Setsuo Hirohashi
Journal:  Cancer Res       Date:  2002-05-15       Impact factor: 12.701

10.  PGP9.5 as a candidate tumor marker for non-small-cell lung cancer.

Authors:  K Hibi; W H Westra; M Borges; S Goodman; D Sidransky; J Jen
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

View more
  30 in total

1.  Prognostic relevance of ubiquitin C-terminal hydrolase L1 (UCH-L1) mRNA and protein expression in breast cancer patients.

Authors:  Christine Schröder; Karin Milde-Langosch; Florian Gebauer; Katharina Schmid; Volkmar Mueller; Ralph M Wirtz; Catherine Meyer-Schwesinger; Hartmut Schlüter; Guido Sauter; Udo Schumacher
Journal:  J Cancer Res Clin Oncol       Date:  2013-08-31       Impact factor: 4.553

2.  A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma.

Authors:  Myriam Loyo; Mariana Brait; Myoung S Kim; Kimberly L Ostrow; Chunfa C Jie; Alice Y Chuang; Joseph A Califano; Nanette J Liégeois; Shahnaz Begum; William H Westra; Mohammad O Hoque; Qian Tao; David Sidransky
Journal:  Int J Cancer       Date:  2011-03-15       Impact factor: 7.396

3.  Ubiquitin C-terminal hydrolase L1 is required for pancreatic beta cell survival and function in lipotoxic conditions.

Authors:  K Y Chu; H Li; K Wada; J D Johnson
Journal:  Diabetologia       Date:  2011-10-25       Impact factor: 10.122

4.  Ubiquitin C-terminal hydrolase-L1 protects cystic fibrosis transmembrane conductance regulator from early stages of proteasomal degradation.

Authors:  Mark J Henderson; Neeraj Vij; Pamela L Zeitlin
Journal:  J Biol Chem       Date:  2010-02-10       Impact factor: 5.157

Review 5.  Review of the alterations in DNA methylation in esophageal squamous cell carcinoma.

Authors:  Yoshifumi Baba; Masayuki Watanabe; Hideo Baba
Journal:  Surg Today       Date:  2013-01-05       Impact factor: 2.549

6.  Ubiquitin carboxy-terminal hydrolase L1 may be involved in the development of mammary phyllodes tumors.

Authors:  Huang-Chun Lien; Chung-Chieh Wang; Chiun-Sheng Huang; Ya-Wen Yang; Wen-Hung Kuo; Yu-Tung Yao
Journal:  Virchows Arch       Date:  2013-01-05       Impact factor: 4.064

Review 7.  Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications.

Authors:  Keishi Yamashita; Shinichi Sakuramoto; Masahiko Watanabe
Journal:  Surg Today       Date:  2010-12-30       Impact factor: 2.549

8.  Cancer immunoediting from immunosurveillance to tumor escape in microvillus-formed niche: a study of syngeneic orthotopic rat bladder cancer model in comparison with human bladder cancer.

Authors:  Carl-Jørgen Arum; Endre Anderssen; Trond Viset; Yosuke Kodama; Steinar Lundgren; Duan Chen; Chun-Mei Zhao
Journal:  Neoplasia       Date:  2010-06       Impact factor: 5.715

9.  Using a Novel Diagnostic Nomogram to Differentiate Malignant from Benign Parathyroid Neoplasms.

Authors:  Angelica M Silva-Figueroa; Roland Bassett; Ioannis Christakis; Pablo Moreno; Callisia N Clarke; Naifa L Busaidy; Elizabeth G Grubbs; Jeffrey E Lee; Nancy D Perrier; Michelle D Williams
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

10.  Frequent CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in sporadic and hereditary Tunisian breast cancer patients: clinical significance.

Authors:  Fatma Trifa; Sondes Karray-Chouayekh; Zeineb Ben Jmaa; Emna Jmal; Abdelmajid Khabir; Tahia Sellami-Boudawara; Mounir Frikha; Jamel Daoud; Raja Mokdad-Gargouri
Journal:  Med Oncol       Date:  2013-01-13       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.